Not all the risk factors for primary pulmonary hypertension (PPH) are known. Appetite suppressants, including fenfluramine derivatives, are strongly suspected aetiological agents.
Abstract
Not all the risk factors for primary pulmonary hypertension (PPH) are known. Appetite suppressants, including fenfluramine derivatives, are strongly suspected aetiological agents.
In a 5 year retrospective study fenfluramine use was evaluated among patients referred to a medical centre specialising in the management of PPH. Fifteen (20%) of 73 patients with PPH had used fenfluramine: all of them were women and in 10 (67%) there was a close temporal relation between fenfluramine use and the development of ezertional dyspnoea. Initial right heart catbeterisation in the 15 women showed severe resting pulmonary hypertension (mean (SD)) with pulmonary artery pressure (PAP) 57 (9) mm Hg, cardi index 2*1 (0-5) Iminim', and pulmonary vascular resastance (PVR) 29 (10) Uhm'. Shortterm epoprostenol infusion produced a significant vasodilator response in 10 patients (mean fall in PVR 24 (15%.) compared with control values). Three fenfluramine users with PPH showed spontaneous clinical and haemodynamic improvement 3, 6 and 12 months after drug withdrawal but there was no significant difference in overall survival (transplant recipients excluded) between fenflurmne users and controls. Histological e mnation of lung tissue from five women who had used fenfluramine and 22 controls, with PPH showed features typical of advanced plexogenic pulmonary arteriopathy in all.
These results do not accord with earlier reports that PPH associated with fenfluramine is less severe and has a better outcome. Fenfluramine may be one aetiological agent that can precipitate or hasten the development of PPH. The results of a European case-control study should give new insights into risk factors for PPH and the cause and effect relation with fenfluramine.
(Br Heart J 1993;70:537-54 1) Primary pulmonary hypertension (PPH) is a devastating disease, with an unknown pathogenesis. However, there is evidence that some aetiological factors can influence the expression of the disease in "susceptible" individuals.' These factors include appetite suppressant drugs, which have been strongly implicated since the 1960s, because of an outbreak of PPH in Western Europe related to the intake of aminorex fumarate.2A In sporadic cases of PPH associated with the use of fenfluramine derivatives reported since then remission was supposed to be common and survival better than in PPH in general.5-"2 Consumption of appetite suppressants, mainly dexfenfluramine, has increased dramatically in European countries over the past 5 years, generally by women aged 20-60. 13 Since 1988 when we saw our first case of PPH that was associated with fenfluramine use we have evaluated the proportion of "ever users" of fenfluramine among patients referred to our institution for PPH. Their haemodynamic function, clinical outcome, and survival were compared with those of PPH patients with no history of fenfluramine use who were referred during the same period.
Patients and methods

PATIENTS
Pulmonary hypertension was defined as a mean resting pulmonary artery pressure >25 mm Hg during right heart catheterisation, with a mean pulmonary wedge pressure below 12 mm Hg.14 Potential causes of secondary pulmonary hypertension were excluded on the basis of previously defined criteria.'4 We excluded patients with PPH and concomitant portal hypertension or HIV infection (which may be another aetiological agent in PPH)."
Among other disease states and risk factors known to be associated with PPH14 we paid special attention to a history of the use of appetite suppressant drugs, especially fenfluramine derivatives (dl-fenfluramine or dexfenfluramine or both), and their effects on the clinical course of PPH (onset and worsening or improvement after withdrawal of the drug). At the time of first evaluation ever users of fenfluramine were classified as current or previous users: current users were those patients in whom symptoms suggestive of PPH had appeared or worsened during fenfluramine use; previous users were patients whose symptoms developed after fenfluramine use stopped and included "recent users" (whose symptoms occurred less than a year after the end of treatment) and "remote users" (whose symptoms began more than one year after the end of fenfluramine use). (14) Functional class (NYHA) I or-II (n (%)) 5 (33) Im or IV (n(%)) 10 (67) Syncope or near-syncope (n (%)) 6 (40) Chest pain (n (%)) 6 (40) Haemoptysis (n (%)) 2 (13) Right ventricular insufficiency (n (%))
(33) Associated conditions:
Raynaud's phenomenon (n (%)) 3 (20) Antinuclear antibody titre >1/80 (n (%/c,)) 2 (13) Migraines (n (%)) 3 (20) NYHA, New York Heart Association. *Ratio.
Primary pudmonary hypertnsion n andfenfluramine use the patients were women (aged 26-58). Most of the reported cases (8/10) were related to the use of dl-fenfluramine,5-"0 whereas two other cases were linked to the more recently marketed dexfenfluramine." 12 We report 15 additional cases of PPH in which fenfluramine may have influenced the expression and/or outcome of the disease. Though our series is much smaller than the 1960s PPH outbreak related to aminorex it raises the question of an association between fenfluramine exposure and PPH. In our series the number of patients with PPH possibly related to fenfluramine use increased recently: two thirds of our cases were diagnosed between January 1991 and December 1992. This seems to parallel the increase in dexfenfluramine consumption in Europe. '3 Because our hospital is a major referral centre for the management of PPH all our patients with PPH were referred for diagnosis and treatment and not because of fenfluramine exposure. The overall population of patients with PPH investigated in our institution over the past 4 years has remained stable at around 20 to 30 new cases per year. The proportion of fenfluramine users among current PPH patients was 20% of the overall patient population and 28% of all women (15/53 ). This rate is probably higher than the proportion of fenfluramine users among-women of the same age in France.
Eight patients in the present series (four current and four recent users) developed exertional dyspnoea approximately 12 months after the start of treatment, a similar interval to that reported by Gurtner at the time of the aminorex epidemic2" and to previous reports of fenfluramine-related PPH cases of which 6/10 were current or recent fenfluramine users when symptoms occurred.5 l" In the five remaining current users, who developed dyspnoea shortly before fenfluramine use, the influence of the drug seemed to be particularly obvious in two of them who definitely worsened after 2 months' exposure, with increased dyspnoea and nearsyncope on exertion. This suggests that fenfluramine may not only precipitate but may also hasten the course of the disease. A similar clinical course has already been reported in a patient with fenfluramine-related PPH who was rechallenged.5 The role of fenfluramine may be more questionable in the two remote users, though there are reports of two patients in whom symptoms developed 2 and 3 years respectively after fenfluramine use.68 Combination treatment with other appetite suppressants, which has been reported in series and individuals with appetite-suppressant-related PPH,3 was also noted in 6/15 of our fenfluramine users. In at least 10/15 (67%) fenfluramine ever users in the present series there seemed to be a close temporal relation between the period of use and the development of PPH, which was diagnosed shortly after onset or worsening of symptoms. As in all previously reported cases of PPH associated with fenfluramine use5"2 all our fenfluramine ever users were female. Though a female predominance is characteristic of PPH, the sex ratio reported in PPH related to appetite suppressants is much higher than the commonly reported 2:1 value in "pure" PPH.'4 A likely explanation is that women are more likely than men to use appetite suppressants and are also believed to be more susceptible to pulmonary hypertension.'
In the Swiss epidemic the disease progressed more rapidly in the aminorex users than in the non-users and the mean time between onset of complaints and hospital admission was shorter.24 This was true of our fenfluramine users (20 (14) months) and non-users (31 (36) months) but the difference did not reach statistical significance (p = 0 37). Haemodynamic findings during baseline catheterisation showed severe pulmonary hypertension as did earlier studies of fenfluramine-related PPH.5"2 No relation has ever been found between the total duration of the use of appetite suppressants and-the degree of pulmonary hypertension,4 and we found no such relation in our patients. Two thirds of our patients showed a reversible component in pulmonary hypertension (vasodilatation in response to epoprostenol). The three fenfluramine users who showed spontaneous haemodynamic improvement after drug withdrawal showed the greatest vasodilatation in response to epoprostenol, with a decrease in PVR of approximately 45% of baseline values. These patients were current fenfluramine users at the time of diagnosis, and two of them had stopped taking the drug only a few days or weeks before catheterisation: thus their response to epoprostenol may have been measured when their pulmonary vascular tone was still increased by fenfluramine.
It has been suggested that patients with appetite-suppressant-related PPH have a better long-term course and survival than other patients with PPH.3-47 Five of the 10 cases of fenfluramine-related PPH reported earlier definitely showed spontaneous clinical and haemodynamic remission (partial or complete) within 1-3 months after first catheterisation and withdrawal of the drug.5-6 9 12 Better survival was also characteristic of the aminorex epidemic,46 though almost half died within the first 10 years of follow up.4 Half of the survivors were restudied several years after initial diagnosis and all showed a considerable increase in PVR during exercise catheterisation despite almost normal resting haemodynamic variables.4 This suggests persistence of underlying pulmonary arteriolar disease, as we found in our only fenfluramine user with a long lasting remission (case 2). Remission of PPH after drug withdrawal, however, was not the rule in most of the fenfluramine users we report and the idea of a better prognosis is not supported by their survival rate, which was not significantly better than that of the control PPH patients, who were evaluated and treated in the same manner and had comparable baseline clinical and haemodynamic characteristics.
The mechanisms responsible for pulmonary hypertension m patients using fenflu-Primary pulmonary hyperrnsion andfenfluramine use ramine or other amphetamine-related appetite suppressants are unclear. Most of these drugs, including fenfluramine, are structurally related and their anorectic activity is attributable to the phenylethylamine molecule.'8 They all have sympathomimetic and serotoninergic effects to various degrees: the latter involve blocking of cellular uptake and metabolism of serotonin, inhibition of monoamine oxidase activity and, more generally, release of large amounts of serotonin from cellular stores (platelets, nerve endings). ' 
